Search and analyze individual stocks with comprehensive metrics

Syncom Formulations (India) Limited

SYNCOMFPharmaceuticals & Biotechnology

Fundamental Score

...

Syncom Formulations (India) Limited Share Price & Market Analysis

Current Market Price (CMP)
17.16
No change data available
Market Cap
1.61K (Cr)
Industry
Pharmaceuticals & Biotechnology

Profitability Metrics

Average

Return on Equity

15.50%
Good

Return on Capital Employed

18.59%
Good

Operating Profit Margin (5Y)

11.41%
Poor

Dividend Yield

0.00%

Valuation Metrics

Good

Price to Earnings

28.33x

Market Capitalization

1.61K (Cr)

Industry P/E

33.97x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

105.77%
Excellent

YoY Quarterly Sales Growth

34.23%
Excellent

Sales Growth (5Y)

17.51%
Excellent

EPS Growth (5Y)

23.05%
Excellent

Profit Growth (5Y)

27.71%

Financial Health

Excellent

Debt to Equity

0.01x
Excellent

Interest Coverage

107.80x
Poor

Free Cash Flow (5Y)

-10.56 (Cr)

Ownership Structure

Good

Promoter Holding

50.57%
Poor

FII Holding

0.41%
Poor

DII Holding

0.00%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
50.57%
Promoter Holding
1.61K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of SYNCOMF across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (15.50%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (18.59%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Robust Profit Growth (105.77%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (34.23%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (17.51% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Excellent EPS Growth (23.05% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (27.71% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (107.80x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (50.57%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

3 factors identified

Negative Free Cash Flow (₹-10.56 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

Limited Institutional Interest (FII+DII: 0.41%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

📊 Educational Market Overview

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Syncom Formulations (India) Limited

About SYNCOMF

Company Details

Symbol:SYNCOMF
Industry:Pharmaceuticals & Biotechnology
Sector:Pharmaceuticals

Market Information

Market Cap:1.61K (Cr)
P/E Ratio:28.33
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.00%

SYNCOMF Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)15.50%
Return on Capital Employed18.59%
Operating Profit Margin (5Y)11.41%
Debt to Equity Ratio0.01
Interest Coverage Ratio107.80

Growth & Valuation

Sales Growth (5Y)17.51%
Profit Growth (5Y)27.71%
EPS Growth (5Y)23.05%
YoY Quarterly Profit Growth105.77%
YoY Quarterly Sales Growth34.23%

Frequently Asked Questions

What is the current price of SYNCOMF?

SYNCOMF is currently trading at ₹17.16 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of SYNCOMF shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of SYNCOMF and what does it mean?

SYNCOMF has a P/E ratio of 28.33x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹28 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.

How is SYNCOMF performing according to Bull Run's analysis?

SYNCOMF has a Bull Run fundamental score of 67.6/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 15.50%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does SYNCOMF belong to?

SYNCOMF operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Syncom Formulations (India) Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for SYNCOMF?

SYNCOMF has an ROE of 15.50%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Syncom Formulations (India) Limited generates profits from shareholders' equity. An ROE of 16% means the company generates ₹16 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is SYNCOMF's debt-to-equity ratio and what does it indicate?

SYNCOMF has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk. This means the company has ₹1 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.

What is SYNCOMF's dividend yield and is it a good dividend stock?

SYNCOMF offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has SYNCOMF grown over the past 5 years?

SYNCOMF has achieved 5-year growth rates of: Sales Growth 17.51%, Profit Growth 27.71%, and EPS Growth 23.05%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in SYNCOMF and why does it matter?

Promoters hold 50.57% of SYNCOMF shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does SYNCOMF compare with its industry peers?

SYNCOMF trades at P/E 28.33x vs industry average 33.97x, with ROE of 15.50% and ROCE of 18.59%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether SYNCOMF is outperforming its competitive set in profitability, growth, and valuation metrics.

What is SYNCOMF's market capitalization and what category does it fall into?

SYNCOMF has a market capitalization of ₹1613 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for SYNCOMF?

Key ratios for SYNCOMF: ROE 15.50% (Excellent), ROCE 18.59%, P/E 28.33x, Debt-to-Equity 0.01, Interest Coverage 107.80x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is SYNCOMF stock and what is its beta?

SYNCOMF has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for SYNCOMF?

SYNCOMF has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹17.16, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in SYNCOMF?

Key risks for SYNCOMF include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.01), and operational challenges. The stock has a Fundamental Score of 67.6/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is SYNCOMF's operating profit margin and how has it trended?

SYNCOMF has a 5-year average Operating Profit Margin (OPM) of 11.41%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.

How is SYNCOMF's quarterly performance in terms of sales and profit growth?

SYNCOMF's recent quarterly performance shows YoY Sales Growth of 34.23% and YoY Profit Growth of 105.77%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in SYNCOMF?

SYNCOMF has FII holding of 0.41% and DII holding of 0.00%, totaling 0.41% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.